Eagle Asset Management Inc Halozyme Therapeutics, Inc. Transaction History

Eagle Asset Management Inc

$16.7 Billion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	SELL	$33.32 - $42.1 $11.4 Million - $14.4 Million	-343,091 Reduced 59.65%	232,113 $8.58 Million
Q3 2023 Nov 13, 2023	SELL	$36.46 - $44.03 $432,743 - $522,592	-11,869 Reduced 2.02%	575,204 $22 Million
Q2 2023 Aug 09, 2023	SELL	$30.28 - $38.74 $6.4 Million - $8.19 Million	-211,289 Reduced 26.47%	587,073 $21.2 Million
Q1 2023 May 08, 2023	SELL	$32.86 - $55.7 $8.93 Million - $15.1 Million	-271,629 Reduced 25.39%	798,362 $30.5 Million
Q4 2022 Feb 14, 2023	SELL	$40.06 - $59.44 $10.2 Million - $15.2 Million	-255,028 Reduced 19.25%	1,069,991 $60.9 Million
Q3 2022 Nov 07, 2022	SELL	$38.53 - $51.78 $2.69 Million - $3.61 Million	-69,718 Reduced 5.0%	1,325,019 $52.4 Million
Q2 2022 Aug 10, 2022	BUY	$37.35 - $48.3 $7.34 Million - $9.5 Million	196,630 Added 16.41%	1,394,737 $61.4 Million
Q1 2022 May 12, 2022	SELL	$31.97 - $41.06 $1.87 Million - $2.4 Million	-58,435 Reduced 4.65%	1,198,107 $47.8 Million
Q4 2021 Feb 11, 2022	SELL	$31.82 - $40.75 $6.7 Million - $8.58 Million	-210,546 Reduced 14.35%	1,256,542 $50.7 Million
Q3 2021 Nov 10, 2021	SELL	$38.47 - $46.42 $8.87 Million - $10.7 Million	-230,454 Reduced 13.58%	1,467,088 $59.7 Million
Q2 2021 Aug 11, 2021	SELL	$38.84 - $51.31 $2.89 Million - $3.82 Million	-74,458 Reduced 4.2%	1,697,542 $77.1 Million
Q1 2021 May 14, 2021	SELL	$39.51 - $51.45 $3.5 Million - $4.56 Million	-88,706 Reduced 4.77%	1,772,000 $75.2 Million
Q4 2020 Feb 12, 2021	SELL	$25.81 - $43.62 $7.18 Million - $12.1 Million	-278,015 Reduced 13.0%	1,860,706 $79.5 Million
Q3 2020 Nov 12, 2020	BUY	$25.74 - $29.63 $716,859 - $825,195	27,850 Added 1.32%	2,138,721 $56.7 Million
Q2 2020 Aug 12, 2020	SELL	$16.25 - $26.81 $47,401 - $78,204	-2,917 Reduced 0.14%	2,110,871 $54.5 Million
Q1 2020 May 11, 2020	BUY	$13.9 - $21.83 $8.08 Million - $12.7 Million	581,647 Added 37.96%	2,113,788 $38 Million
Q4 2019 Feb 07, 2020	SELL	$14.93 - $19.53 $126,531 - $165,516	-8,475 Reduced 0.55%	1,532,141 $27.2 Million
Q3 2019 Nov 04, 2019	BUY	$15.2 - $17.69 $23.4 Million - $27.3 Million	1,540,616 New	1,540,616 $23.9 Million

Others Institutions Holding HALO

# of Institutions

543

Shares Held

125M

Call Options Held

294K

Put Options Held

180K

Black Rock Inc. New York, NY

17.6M
Shares

$838 Million
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

12.9M
Shares

$613 Million
0.01% of portfolio
State Street Corp Boston, MA

6.63M
Shares

$315 Million
0.02% of portfolio
Snyder Capital Management L P San Francisco, CA

4.06M
Shares

$193 Million
5.07% of portfolio
Alliancebernstein L.P. New York, NY

3.41M
Shares

$162 Million
0.07% of portfolio

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.62B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eagle Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Eagle Asset Management Inc with notifications on news.

Account